ArticleAnalytical chemistry2015
Using DNA aptamer probe for immunostaining of cancer frozen tissues.
Article in Analytical chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Preliminary assessment of biodistribution and targeting of the fluorescent molecular probe Cy7-SYL3C in an EpCAM-positive colorectal cancer mouse model.Scientific reports · 2026Article
- Dynamic PET Imaging of EpCAM-Positive Colorectal Cancer Using Radiolabeled DTN-SYL3C Aptamer Conjugates.ACS omega · 2025Article
- Potential determinants of low circulating glucagon-like peptide 2 concentrations in Zambian children with non-responsive stunting.Experimental physiology · 2023Article
- Recent advances in optical aptasensor technology for amplification strategies in cancer diagnostics.Analytical and bioanalytical chemistry · 2020Review
- SYL3C aptamer-anchored microemulsion co-loading β-elemene and PTX enhances the treatment of colorectal cancer.Drug delivery · 2019Article
- RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma.Molecular therapy. Nucleic acids · 2019Article
- A DNA aptamer recognizing MMP14 forOncology letters · 2019Article
- Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells.Scientific reports · 2019Article
- Review
- An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.Theranostics · 2018Article
- Aptamer selection and applications for breast cancer diagnostics and therapy.Journal of nanobiotechnology · 2017Review
- DNA mimics of red fluorescent proteins (RFP) based on G-quadruplex-confined synthetic RFP chromophores.Nucleic acids research · 2017Article
- Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Scientific reports · 2017Article
- An 'activatable' aptamer-based fluorescence probe for the detection of HepG2 cells.Oncology reports · 2017Article
- Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility.Histochemistry and cell biology · 2017Review
- Advances in the development of aptamer drug conjugates for targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma.Molecular therapy. Nucleic acids · 2017Article
- Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology.Journal of the American Chemical Society · 2017Article
- Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology.NPJ precision oncology · 2017Review
- Fluorescence resonance energy transfer-based hybridization chain reaction forChemical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Tissue immunostaining is critically important in clinical applications, and antibodies have been used extensively as the molecular probes. Recently, aptamer, as a new class of probes, have attracted much attention for their potential clinical and research value. Epithelial cell adhesion molecule (EpCAM) is a specific biomarker which is overexpressed in many cancers of epithelial origin. Here, a DNA-based EpCAM aptamer SYL3C is reported as a probe for the immunostaining of frozen and paraffin-embedded sections of colorectal cancer tissues. Commercialized EpCAM antibodies were also used as a standard control. EpCAM aptamer SYL3C specifically recognized and immunostained cancer nests of colorectal tumor sections, but it neither reacted with background cells within tumor sites nor exhibited cross-reaction to the benign lesions or inflammation of colorectal tissues. No cross-linking to EpCAM-negative malignant tumor sections occurred. Compared with standard antibody staining, our EpCAM aptamer SYL3C protocol is simpler to implement with a shorter reaction time. Moreover, SYL3C can specifically bind with either frozen or paraffin-embedded tissue sections. Since the histopathology of frozen tissue is closer to that of fresh tissue and since frozen sections can be produced more quickly than paraffin-embedded sections, SYL3C immunostaining of frozen sections is a quick protocol that is easy to implement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.